XEMPERIA
LIVE

Serial Number

79394728

Owner

Curzio Rüegg

Attorney

Robert T. Maldonado

Filing Date

Feb 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

XEMPERIA Trademark

Serial Number: 79394728 • Registration: 7910012

XEMPERIA is a trademark filed by Curzio Rüegg on February 8, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 38 (Telecommunications), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Curzio Rüegg (2 trademarks)

Rue du Vieux Pont 61

Entity Type: 01

Trademark Details

Filing Date

February 8, 2024

Registration Date

August 26, 2025

Published for Opposition

June 10, 2025

Goods & Services

Diagnostic biomarker, namely, nucleic acids, proteins in raw form, reagents, and preparations, for analytical, research and scientific use, other than for medical or veterinary purposes.

Scientific and technological services for medical, biomedical and genetic purposes, namely, scientific analysis, DNA and RNA screening, and pathological testing for medical research purposes in the field of cancer and immune and inflammatory conditions as well as research and design relating thereto; industrial analysis and research services, namely, biological and molecular analyses and research; scientific and medical research and development in the field of cancer and immune and inflammatory conditions; research and development in the field of biotechnology; research in the field of chemistry and biology; research in the field of biochemistry; scientific research for medical purposes in the field of cancer and immune and inflammatory conditions; research and development in the field of diagnostic preparations; medical and scientific research in the field of cancer diagnosis and treatment; development and early evaluation of new pharmaceutical products; testing of pharmaceutical products; research and development of new products; pharmaceutical research and development services; scientific and technological services, namely, computer-aided scientific research, testing and analysis services in the field of cancer and immune and inflammatory conditions; medical and scientific research, namely, conducting clinical trials for others; conducting of scientific feasibility studies; scientific and technological services, namely, scientific analyses in the field of cancer and immune and inflammatory conditions; scientific and technological services, namely, scientific research, testing and analysis services in the field of cancer and immune and inflammatory conditions; consultant services in the field of scientific and industrial research in the field of cancer and immune and inflammatory conditions; scientific advisory and information services in the nature of preparation of reports relating to scientific research; scientific advisory and information services in the nature of preparation of scientific research and medical reports; providing information and data with respect to scientific and technological research and development in the field of cancer and immune and inflammatory conditions; providing research information and results in the field of technology, science and medicine from an online searchable database; medical and scientific research, namely, conducting clinical trials for others; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; scientific research services for third parties in the field of biotechnology; design and development of computer hardware and software; development and research of new products for third parties; consultancy services relating to biotechnology; research laboratory analysis services with respect to biotechnology, pharmacotherapy, diagnostics, pharmaceutical research and development; pharmaceutical and biological being scientific development and research services for third parties; clinical research in the field of cancer and immune and inflammatory conditions; evaluation of pharmaceutical product development, namely, screening being inspection and testing of pharmaceuticals; research in the field of pharmaceutical products; laboratory research in the field of medicinal and analytical chemistry, biology, pharmacology and toxicology; clinical research and testing services in the field of cancer and immune and inflammatory conditions; analytical laboratory services being scientific laboratory services; scientific and technological services, namely, technical analysis and scientific laboratory report drafting services for the purposes of diagnosis, prognosis and prediction of cancer and related diseases; services for the development and testing of pharmaceutical drugs; research and development of pharmaceuticals, medical devices, biotechnologies and biochemicals; technical research in the field of cancer and immune and inflammatory conditions; conducting technical studies and projects, namely scientific and clinical validation studies being cancer detection and pharmaceutical studies; computer system analysis; scientific consulting services for third parties in the field of clinical and non-clinical studies and trials on pharmaceuticals and medical devices; hosting an online website featuring computer databases in the fields of research and development of pharmaceuticals, medical devices, biotechnologies and biochemicals; hosting an online website featuring medical tests for scientific research purposes, testing for forensic research purposes, testing for quality control purposes, genetic testing for scientific research purposes, as well as medical and scientific research in the field of diseases, medical care, healthcare, pharmaceuticals, medical devices, biochemicals and biotechnology; providing, for temporary use, online non-downloadable applications and software for use in studying, diagnosing or screening for cancer and studying genetics and DNA; providing, for temporary use, online non-downloadable cloud computing software for use in studying, diagnosing or screening for cancer and studying genetics and DNA; hosting an Internet website portal in the nature of hosting an online website featuring information on the results of medical tests of patients derived from medical tests for diagnostic or treatment purposes; hosting an Internet website portal in the nature of hosting an online website featuring links to medical information.

Equipment for data processing and computers; downloadable data banks in the field of human health and cancer biostatistics; downloadable computer programs for data search, collection, management, storage and analysis; data processing apparatus; downloadable software in the field of medical diagnostics for interpretation of gene and protein expression provided by diagnostic equipment; downloadable software for laboratory instruments for gene and protein expression analysis; downloadable computer software for the diagnosis of human diseases; laboratory equipment and instruments, namely, thermocyclers for research use, flow cytometers for scientific, laboratory, and general research uses; laboratory equipment and instruments for diagnostic analysis namely, thermocyclers, and flow cytometers; downloadable mobile applications for accessing, monitoring and sharing patient medical information in the field of disease diagnosis and treatment; downloadable electronic publications in the nature of medical books, magazines, brochures, and user's instruction manuals in the field of pathology, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions.

Medical services; health screening in the field of cancer and inflammatory conditions and medical diagnostic services; medical analysis services for the purposes of screening, diagnosis or treatment of cancer and prognosis of the progression of diseases; medical diagnosis of cancer and immune and inflammatory conditions; diagnosis in the field of medicine, namely cancer and immune and inflammatory conditions; medical laboratory services for the analysis of blood samples for diagnostic purposes; blood analysis services for diagnostic purposes provided by medical laboratories; medical analysis and testing services for screening, diagnostic or treatment purposes in the field of cancer; providing medical tests and reporting services for diagnostic, prognostic and predictive purposes for cancer and related diseases; providing diagnostic, prophylactic and therapeutic information in the fields of disease, medical care and healthcare; advisory services in the field of health; medical advisory services in the pharmaceutical field; medical advice concerning the preparation of diagnoses; provision of health information; providing health screening services in the field of cancer and immune and inflammatory condition, risk assessment in the field of health, customized profiles being health assessments in the field of health, and evaluation being assessment in the field of health for consumers, healthcare professionals, healthcare institutions, pharmacies and pharmaceutical product manufacturers; providing online information via an Internet website portal offering information on the results of medical tests of patients derived from medical tests for diagnostic or treatment purposes; providing information via an Internet website portal offering links to medical information.

Pharmaceutical and veterinary products, namely, pharmaceutical preparations for treating cancer and immune and inflammatory conditions; diagnostic products being preparations for medical use; pharmaceutical healthcare preparations for treating cancer and immune and inflammatory conditions; medicinal substances and preparations for therapeutic use, namely, for treating cancer and immune and inflammatory conditions; medical substances and preparations for the treatment and prevention of diseases, namely, for treating cancer and immune and inflammatory conditions; biochemical preparations for medical use; biological preparations for medical use, chemical preparations for medical use, namely, for treating cancer and immune and inflammatory conditions; chemical preparations for pharmaceutical use, namely, for treating cancer and immune and inflammatory conditions; biotechnological preparations for medical use, namely, for treating cancer and immune and inflammatory conditions; diagnostic preparations for medical use; in-vitro diagnostic preparations for medical use; diagnostic preparations in the nature of blood tests, namely, venipuncture for measuring nucleic acids, proteins in blood leukocytes; diagnostic kits comprising chemical reagents used for diagnostic purposes for medical use; diagnostic kits comprising reagents for diagnostic tests for medical use; health screening kits comprised of medical diagnostic reagents for screening blood and other bodily fluids and diagnosis for medical use; biological, chemical and biochemical reagents for medical use, namely, for treating cancer and immune and inflammatory conditions; diagnostic test reagents for medical or veterinary use; reagents for medical use; diagnostic reagents for medical or veterinary use; biological and chemical reagents for medical or veterinary use, namely, for treating cancer and immune and inflammatory conditions; diagnostic biomarking reagents for medical use; diagnostic biomarker reagents for analytical use for medical purposes; reagents for genetic testing for medical use and medical diagnostics; medical diagnostic test, namely, venipuncture, blood, leucocyte analysis, PCR and hybridization molecular analysis, and algorithmic analysis, and reagents for analysing blood and organic fluid; genetic identity tests comprised of reagents for medical use; diagnostic reagents and imaging contrast agents for medical use; contrast products, namely, imaging contrast agents for in-vivo imaging; cells for medical or veterinary use; biological tissue cultures for medical use; cell therapy preparations, namely, leukocytes; cell preparations for humans or animals adapted for medical or therapeutic use, namely, leukocytes.

Providing access to the Internet; providing online access to an electronic exchange of medical records across a nationwide health information network featuring information on the results of medical tests of patients derived from medical tests for diagnostic or treatment purposes and links to medical information; providing multiple-user access to data on the Internet in the field of medical test results of patients derived from medical tests for diagnostic or treatment purposes and medical information.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 26, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 9, 2026 FICS
FINAL DISPOSITION PROCESSED
Mar 9, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 25, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 10, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 10, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 26, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 26, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 26, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 10, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 10, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 4, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 7, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 15, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 15, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 15, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 14, 2025 GNFN
FINAL REFUSAL E-MAILED
Mar 14, 2025 GNFR
FINAL REFUSAL WRITTEN
Mar 14, 2025 CNFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 20, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 20, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 20, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 20, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 20, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 20, 2025 COAR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 20, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 20, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 20, 2025 TROA
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 22, 2024 CORN
REFUSAL PROCESSED BY IB
Sep 30, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 4, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 4, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 4, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 3, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 2, 2024 DOCK
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 13, 2024 CRCV
APPLICATION FILING RECEIPT MAILED
May 10, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 10, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 2, 2024 REPR